As of today (2026-06-26), the Forward Annual Dividend Yield of AnaptysBio is 0.00%.
As of today (2026-06-26), the Trailing Annual Dividend Yield of AnaptysBio is 0.00%.
STU:AN6's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.495 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
STU:AN6 vs VIR, GHRS, INVA: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, AnaptysBio's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AnaptysBio Forward Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AnaptysBio's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where AnaptysBio's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
AnaptysBio (STU:AN6) has a Forward Dividend Yield % of 0.00% as of Jun. 26, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on AnaptysBio and its competitors. According to the industry distribution chart, AnaptysBio ranks #999999 out of 146 companies in the Biotechnology industry.
Is AnaptysBio's Forward Dividend Yield % too high?
AnaptysBio's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, AnaptysBio ranks #999999 out of 146 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, AnaptysBio has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does AnaptysBio's Forward Dividend Yield % compare to VIR and GHRS?
According to the Biotechnology industry distribution chart, AnaptysBio ranks #999999 out of 146 companies for Forward Dividend Yield %. This places AnaptysBio in the lower half of its industry. The industry median Forward Dividend Yield % is 1.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.50, based on 146 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on AnaptysBio and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AnaptysBio's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AnaptysBio stock overvalued right now?
AnaptysBio (STU:AN6) has a current Forward Dividend Yield % of 0.00%. The stock's GF Value™ is €54.21, compared to a current price of €51.76 — trading 4.5% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. AnaptysBio's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For AnaptysBio (STU:AN6), the current Forward Dividend Yield % is 0.00% as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AnaptysBio (STU:AN6) Overvalued in 2026?
Based on GuruFocus' analysis, AnaptysBio stock appears to be undervalued.
The current stock price of €51.76 is trading 4.5% below its estimated GF Value™ of €54.21.
Key valuation signals for STU:AN6:
Forward Dividend Yield %: 0.00%
GF Value™: €54.21 vs. price of €51.76 (4.5% below fair value)
No single metric tells the full story. See the STU:AN6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
67GF Score
Get the complete analysis for STU:AN6
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:AN6 has been successfully added to your 